Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
CURRICULUM VITAE NAME Mototsugu Oya, M.D. IDENTICAL INFORMATION Title: Professor and Chairman, Department of Urology, Keio University School of Medicine E-mail: [email protected] EDUCATIONAL HISTORY Sep/1994 Mar/1987 Doctor of Medical Science. Keio University, School of Medicine,Tokyo, Japan M.D. Keio University, School of Medicine, Tokyo, Japan PROFESSIONAL BACKGROUND (EMPLOYMENT HISTORY) Oct/2013:-present Aug/2007-present Vice Director, Keio University Hospital Professor and Chairman, Department of Urology, Keio University School of Medicine Apr/2001-Jul/2007 Assistant Professor, Department of Urology, Keio University School of Medicine (Aug/2004-Jul/2006 Program Officer, Ministry of Education, Culture, Sports, Science and Technology) Oct/1998-Mar/2001 Medical Staff, Department of Urology, Keio University Hospital Jan/1997-Sep/1998 Postdoctoral fellow, Department of Urology, Duesseldorf University, Germany Apr/1996-Oct/1996 Medical Staff, Division of Urology, Ogikubo Hospital, Tokyo Jan/1995-Mar/1996 Postdoctoral fellow, Department of Urology, New York Medical College, USA Jun/1993-Nov/1994 Medical Staff, Division of Urology, Saiseikai Chuou Hospital, Tokyo Jun /1987-May/1993 Resident atDepartment of Urology, Keio University Hospital Jun/1987: passed the Examination of National Board LICENSE AND CERTIFICATION 1987 1993 2003 2003 2008 2008 Japanese Japanese Japanese Japanese Japanese Japanese Medical License Registration Board of Urology, Certified Urologist Board of Nephrology, Certified Doctor Board of Dialysis Medicine, Certified Doctor Board of Cancer Treatment, Certified Doctor Society of Endourology & ESWL , Certified Laparoscopic Surgeon MEMBERSHIP (selected) Japanese Urological Association (director) Japanese Society of Cancer (councilor) Japanese Society of Clinical Oncology (councilor) Japanese Society of Endourology and ESWL (councilor) Japanese Society of Nephrology (councilor) Japanese Society of Dialysis Medicine SociétéInternationale d’Urologie American Urological Association European Association of Urology PRIZE Japanese Urological Association Prize 2005 Organon Urological Research Grant 2006 Japanese Urological Association Research Grant 2011 SPECIALIZED FIELDS Urology, Oncology, Nephrology, Dialysis, Cancer Biology, Immunology, Molecular Medicine EDITORIALES FOR SPECIFIC JOURNALES International Journal of Urology (Editor-in-Chief) Cancer Science (Associated editor) International Case Conference Journal (Associated editor) Clinical and Experimental Nephrology (Associate editor) World Journal of Urology(Editor) International Journal Clinical Oncology (Editor) Japanese Journal of Clinical Oncology (Editor) Japanese Journal of Urology (Editor-in-Chief) Japanese Journal of Clinical Urology (Editor-in-Chief) Japanese Journal ofDialysis Medicine (Associate editor) BIBLIOGRAPHY: PUBLICATIONS 1. Oya M: Antitumor effect of interleukin-2 entrapped in liposomes on murine renal cell carcinoma: Keio J Med, 43, 37-44, 1994. 2. Oya M, Nakamura K, Baba S, Hata J, Tazaki H: Intrarenal satellites of renal cell carcinoma: Histopathological manifestation and clinical implication: Urology, 46, 161-164, 1995. 3. Baba S, Asanuma H, Oya M: Laparoscopy assisted orchiopexy. –Technical feasibility and indications– Jpn J EVndourol: ESWL, 8, 144-147, 1995. 4. Oya M, Marumo K, Murai M, Tazaki H: Pharmacokinetics and antitumor effects of an interleukin-2 immunocomplexing agent in murine renal cell carcinoma: Int J Urol, 3, 141-144, 1996. 5. Marumo K, Oya M, Murai M, Tazaki H: Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma: Int J Urol, 3, s24-s27, 1996. 6. Oya M, Konno S, Chen Y, Tazaki H, Mallouh C, Wu J. M: Control of cell cycle regulatory proteins andmodulation of STAT1 proteins by IFN-γ in human prostatic JCA-1 cells: Int J Oncol, 10, 835-839, 1997. 7. Marumo K, Oya M, Murai M: Application of interferon minipellet to human renal cell carcinoma in nude mice: Int J Urol, 4, 55-61, 1997. 8. Marumo K, Oya M, Murai M: Biochemical modulation of 5-fluorouracil with murine interferon–α/βagainst murine renal cell carcinoma: Int J Urol, 4, 163-168, 1997. 9. Oya M, Schmidt B, Schmitz-Dräger B.J, Schulz.W. A: Expression of G1S transition regulatory molecules in human urothelial cancer: Jpn J Cancer Res, 89, 719-726, 1998. 10. Oya M, Schulz W.A: Decreased expression of p57 KIP2 mRNA in human bladder cancer: Br J Cancer, 83, 626-631, 2000. 11. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer: Clin Cancer Res, 6, 2702-2706, 2000. 12. Nakashima J, Ozu C, Nishiyama T, Oya M, Ohigashi T, Asakura H, Tachibana M, Murai M: Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy: Urology, 56, 843-847, 2000. 13. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M: Constitutive activation of nuclear fctor-B prevents TRAIL-induced apoptosis in renal cancer cells: Oncogene, 20, 3888-3896, 2001. 14. Horiguchi A, Oya M, Marumo K, Murai M: STAT3, but not ERKs mediates IL-6-induced proliferation of renal cancer cells, ACHN and 769P: Kidney Int, 61, 926-938, 2002. 15. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M: Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome: J Urol, 168, 762-765, 2002. 16. Horinaga M, Nakashima J, Ishibashi M, Oya M, Ohigashi T, Marumo K, Murai M: Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: the usefulness of complicated prostate specific antigen adjustedfor transition zone volume: J Urol, 168, 986-990, 2002. 17. Marumo K, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Asakura H, Nakashima J, Murai M: Significance and diagnostic accuracy of renal calculi found by ultrasonography in patients with asimptomatic microscopic hematuria: Int J Urol, 9, 363-369, 2002. 18. Oya M, Takayanagi A, Horiguchi A, Mizuno M, Ohtsubo M, Marumo K, Shimizu N, Murai M: Increased nuclear factor-B activation is related to the tumor development of renal cell carcinoma: Carcinogenesis, 24, 377-384, 2003. 19. Oya M, Horiguchi A, Mizuno M, Marumo K, Murai M: Increased activation of CCAAT/enhancer binding protein-correlates with the invasiveness of renal cell carcinoma: Clin Cancer Res, 9, 1021-1027, 2003. 20. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M: Elevated AKT activation and its impact on clinicopathological features of renal cell carcinoma: J Urol, 169, 710-713, 2003. 21. Kikuchi E, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M: Enhancement of Diethylstilbestrol induced cytotoxicity by Bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer: J Urol, 169, 730-734, 2003. 22. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M: Suppression of hormone-refractory prostate cancer bya novel nuclear factor B inhibitor in nude mice: Cancer Res, 63, 107-110, 2003. 23. Horiguchi A, Nakashima J, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Marumo K, Murai M:Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer: The Prostate, 56, 23-29, 2003. 24. Marumo K, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Asakura H, Nakashima J, Murai M: Incidence and growth pattern of simple cysts of the kidney in patients with asymptomatic microscopic hematuria: Int J Urol, 10, 63-67, 2003. 25. Schmidt B, Anastasiadis A.G, Seifert H.H, Franke K.H, Oya M, Ackermann R: Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade: Anticancer Res, 23, 3991-3999, 2003. 26. Ito K, Nakashima J, Hanawa Y, Oya M, Ohigashi T, Marumo K, Murai M: The prediction of renal function 6 years after unilateral nephrectomy using preoperative risk factors: J Urol, 171, 120-125, 2004. 27. Mizuno R, Oya M, Shiomi T, Marumo K, Okada Y, Murai M: Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells: J Urol, 172, 723-727, 2004. 28. Oya M, Mikami S, Mizuno M, Miyajima A, Horiguchi Y, Nakashima J, Marumo K, Mukai M, Murai M :Differential expression of activator protein-2 isoforms in renal cell carcinoma: Urology, 64, 162-167, 2004. 29. Nakashima J, Tanimoto A, Imai Y, Mukai M, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Marumo K, Murai M: Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer: Urology, 64, 101-105, 2004. 30. Ishizawa J, Yoshida S, Oya M, Mizuno R, Shinojima T, Marumo K, Murai M: Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induce apoptosis in renal cancer cells: Int J Oncol, 25, 697-702, 2004. 31. Kanao K, Kikuchi E, Nakashima J, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Marumo K, Murai M: Three-dimensional ultrasonography in evaluation of benign prostatic hyperplasia: Int J Urol, 11, 1087-1091, 2004. 32. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M: Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor: Ann Oncol, 16, 928-933, 2005. 33. Oya M, Mikami S, Mizuno R, Marumo K, Mukai M, Murai, M: C-jun activation in acquired cystic kidney disease and renal cell carcinoma: J Urol, 174, 726-730, 2005. 34. Mizuno R, Oya M, Hara S, Matsumoto M, Horiguchi A, Ohigashi T, Marumo K, Murai M: Modulation of bcl-2 family proteins in MAPK independent apoptosis induced by a cdc25 phosphatase inhibitor Cpd 5 in renal cancer cells: Oncol Rep, 14, 639-644, 2005. 35. Oya M, Asakura H, Mizuno R, Marumo K, Murai M: Repeated regression of pulmonary metastases from renal cell carcinoma after treatment using different interferon-alpha preparations: Biomed Res, 26(3), 135-7, 2005. 36. Sato A, Oya M, Ito K, Mizuno R, Horiguchi Y, Ohigashi T, Umezawa K, Hayakawa M, Murai M: Survivin associates with cell proliferation in renal cancer cells: Regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor: Int J Oncol, 28, 841-846, 2006. 37. Mizuno R, Nakashima J, Mukai M, Ookita H, Nakagawa K, Oya M, Ohigashi, T, Marumo K, Murai M: Maximum tumor diameter is a smple and valuable index associated with the local extent of disease in clinically localized prostate cancer: Int J Urol, 13, 951-955, 2006. 38. Sato A, Ohigashi T, Oya M, Nakashima J, Marumo K, Murai M: Clinicopathological featurtes predicting nodal metastasis of testicular seminoma: results from 100 cases in a single institute: Urol Int, 77, 64-68, 2006. 39. Mikami S, Oya M, Mizuno R, Murai M, Mukai M, Okada Y: Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis: Cancer Sci, 97, 875-882, 2006. 40. Kikuchi E, Nakashima J, Ishibashi M, Ohigashi T, Oya M, Nakagawa K, Miyajima A, Murai M: Usefulness of alpha 1-antichymotripsin-PSA complex for predicting bone metastases of prostate cancer: Urology, 68, 371-375, 2006. 41. Kanao K, Nakashima J, Nakagawa K, Asakura H, Miyajima A, Oya M, Ohigashi T, Murai M: Preoperative nomograms for predicting stone-free rate after extracorporeal shock wave lithotripsy: J Urol, 176, 1453-1457, 2006. 42. Kikuchi E, Horiguchi Y, Nakashima J, Ohigashi T, Oya M, Nakagawa K, Miyajima A, Murai M: Assessment of long-term quality of life using the FACT-BL questionnaire in patients with an ileal conduit, continent reservoir, or orthotopic neobladder: Jpn J Clin Oncol, 36, 723-716, 2006. 43. Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Murai M: Interleukin 6 is associated with cahexia in patients with prostate cancer: Urology, 69, 113-117, 2007. 44. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M: Renal cancer cells lacking hypoxia inducible factor (HIF) 1-expression maintain vascular endothelial growth factor expression through HIF 2-: Carcinogenesis, 28, 529-536, 2007. 45. Nakashima J, Tanimoto A, Kikuchi E, Miyajima A, Nakagawa K, Oya M, Ohigashi T, Murai M: Clinical implications of tumor size and local extent of primary prostatic lesions in prostate cancer patients with metastases: value of endorectal magnetic resonance imaging in patients with metastases: Urology, 70:86-90, 2007. 46. Kosaka T, Mikami S, Miyajima A, Kikuchi E, Nakagawa K, Ohigashi T, Nakashima J, Oya M: Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients: Clin Exp Nephrol, 12,195-199, 2008. 47. Kosaka T, Miyajima A, Kikuchi E, Horiguchi Y, Umezawa K, Ohigasi T, Nakashima J, Asano T, Oya M: The novel NF-kB activation inhibitor dehydroxymethy-epoxyquinomicin suppresses anti-thy1.1-induced glomerulonephritis in rats: Nephron Exp Nephrol, 110, e17-e24, 2008. 48. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M: Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors: J Urol, 180, 1131-1136, 2008. 49. Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, Kosaka T, Mukai M, Nakajima M, Okada Y: Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis: Clin Cancer Res, 14, 6055-6061, 2008. 50. Nishimoto K, Nakashima J, Hashiguchi A, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Oya M, Murai M: Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy gleason score in clinically localized prostate cancer: Int J Urol, 15, 520-523, 2008. 51. Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M: Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer: Int J Urol, 15, 419-422, 2008. 52. Kanai K, Kikuchi E, Ohigashi T, Miyajima A, Nakagawa K, Nakashima J, Oya M: Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.:Int J Clin Oncol, 13(6), 510-4, 2008. 53. Ide H, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M: The predictors of local recurrence after radical cystectomy in patients with invasive bladder cancer: Jpn J Clin Oncol, 38(5), 360-4, 2008. 54. Nakashima J, Kikuchi E, Miyajima A, Nakagawa K, Oya M, Ohigashi T, Murai M: Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases: Urol Int, 80(2), 129-33, 2008. 55. Kikuchi E, Margulis V, Karakiewicz P, Mikami S, Lotan Y, Remzi M, Bolenz C, Zigeuner R, Weizer R, Montorsi F, Bensalah K, Koppie TM, Fernandez MI, Wood CG, Roscigno M, Raman JD, Suardi N, Strobel P, Oya M, ShariatSF: Lymphovascular invasion is a powerful predictor of clinical outcomes in patients with node-negative uppertract urothelial carcinoma: J Clin Oncol, 27(4), 612-618, 2009. 56. Takeda T, Kikuchi E, Yuge K, Matsumoto K, Miyajima A, Nakagawa K, Oya M: Discontinuance of Bacille Calmette-Guerin Instillation Therapy for Nonmuscle-Invasive Bladder Cancer Has Negative Effect on Tumor Recurrence: Urology, 73(6), 1318-1322, 2009. 57. Kosugi M, Miyajima A, Kikuchi E, Kosaka T, Horiguchi Y, Murai M, Oya M: Angiotensin II Type 1 Receptor Antagonist Enhances Cis-dichlorodiammineplatinum-Induced Cytotoxicity in Mouse Xenograft Model of Bladder Cancer: Urology, 73(3), 655-660, 2009. 58. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y: Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas: J Pathol, 218, 530-539, 2009. 59. Uchida Y, Miyajima A, Kikuchi E, Kozakai N, Kosaka T, Ieda M, Fkuda K, Ohigashi T, Oya M: Renal damage inhibited in mice lacking angiotensinogen gene subjected to unilateral ureteral obstruction: Urology, 74(4), 938-943, 2009. 60. Ishida M, Nakashima J, Hashiguchi A, Mizuno R, Shinoda K, Kikuchi E, Miyajima A, Nakagawa K, Mukai M, Oya M: Are predictive models for cancer volume clinically useful in localized prostate cancer?: Int J Urol, 16, 936-940, 2009. 61. Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T, Tomita Y: Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma: British Journal of Caner, 101, 1-10, 2009. 62. Kanai K, Nakashima J, Sugawara A, Shigematsu N, Nagata H, Kikuchi E, Miyajima A, Nakagawa K, Kubo A, Oya M: Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer: Int J Clin Oncol, 14(6), 502-6, 2009. 63. Hasegawa M, Kikuchi E, Yasumizu Y, Hattori S, Takeda T, Morita S, Kosaka T, Miyajima A, Horiguchi T, Mikami S, Oya M: Brain metastasis of a papillary renal cell carcinoma, identified as type 2: Int J Clin Oncol, 14(3), 270-2, 2009. 64. Miyajima A, Kikuchi E, Kosaka T, Oya M: Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer: Rev Recent Clin Trials, 4(2), 75-8, 2009. 65. Mizuno R, Nakashima J, Mukai M, Okita H, Kosugi M, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Oya M: Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer: BJU Int, 104(9), 1215-8, 2009. 66. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T: Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association: Int J Urol, 16(3), 279-86, 2009. 67. Kanao K, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M: Preoperative prognostic nomogram(probability table) for renal cell carcinoma based on TNM classification: J Urol, 181(2), 480-5, 2009. 68. Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernandez MI, Strobel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz PI: Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases: Eur Urol, 53, 2799-2803, 2009. 69. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Monotorsi F, Oya M, Wood CG, Fernandez MI, Evans CP, Koppie TM: Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the upper tract urothelial carcinoma collaboration: J Urol, 182, 900-906, 2009. 70. Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Hasegawa M, Mikami S, Oya M: Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer: Prostate, 70(2), 162-9, 2010. 71. Kanai K, Kikuchi E, Mikami S, Suzuki E, Uchida Y, Kodaira K, Miyajima A, Ohigashi T, Nakashima J, Oya M: Vitamin Esuccinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo: Cancer Sci, 101(1), 216-223, 2010. 72. Ide H, Kikuchi E, Kono H, Nagata H, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M: Docetaxel in combination with prednisolone for hormone refractory prostate cancer: Jpn J Clin Oncol, 40(1), 79-84, 2010. 73. Matsumoto K, Kikuchi E, Horiguchi Y, Tanaka N, Miyajima A, Nakagawa K, Nakashima J, Oya M: Late Recurrence and Progression in Non-muscle-invasive Bladder Cancers After 5-year Tumor-free Periods: Urology, 75(6), 1385-1391, 2010. 74. Ide H, Nakashima J, Kono H, Kikuchi E, Nagata H, Miyajima A, Nakagawa K, Oya M: Prognostic Stratification in Patients Who Received Hormonal Therapy for Prostate-specific Antigen Recurrence after Radical Prostatectomy: Jpn J Clin Oncol, 40(2), 177-80, 2010. 75. Ishida M, Mikami S, Kikuchi E, Kosaka T, Miyajima A, Nakagawa K, Mukai M, Okada Y, Oya M: Activation of the Aryl hydrocarbon receptor pathway enhances cancer cell invasion by up-regulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer: Carcinogenesis, 31(2), 287-95, 2010. 76. Ohigashi T, Kanao K, Mizuno R, Kikuchi E, Nakashima J, Oya M: Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: Development of a novel pre-biopsy nomogram: Int J Urol, 17, 274-280, 2010. 77. Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M: Potent cytotoxic effect of a novel nuclear factor-kB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines: Urology, 75(4), 805-812, 2010. 78. Nishimoto K, Nakagawa K, Li D, Kosaka T, Oya M, Mikami S, Shibata H, Itoh H, Mitani F, Yamazaki T, Ogishima T, Suematsu M, Mukai K: Adrenocortical zonation in humans under normal and pathological conditions: J Clin Endocrinol Metab, 95(5), 2296-2305, 2010. 79. Yoshimine S, Kikuchi E, Matsumoto K, Ide H, Miyajima A, Nakagawa K, Oya M: The clinical significance of urine cytology after a radical cystectomy for urothelial cancer: Int J Urol, 17(6), 527-533, 2010. 80. Miyajima A, Hasegawa M, Takeda T, Tamura K, Kikuchi E, Nakagawa K, Oya M: How do young residents practice laparoscopic surgical skills?: Urology, 76(2), 352-356, 2010. 81. Kaiho Y, Kikuchi E, Oya M, Yoshioka K, Nakagami Y, Hatano T, Ozu C, Horiguchi Y, Namiki K, Tachibana M, Hisasue S, Tanaka N, Asakawa I: Report of the international Journal of Urology editorial board meeting 2010 in Iwate Haruki Kume characteristics and management of erectile dysfunction after various treatments for prostate cancer Jintetsu Soh: Int J Urol, 17(8), 686-688, 2010. 82. Naito S, Tomita Y, Sun Young Rha, Uemura H, Oya M, He Zhi Song, Li Han Zhong, Mohamed Ibrahim Bin A Wahid: Kidney cancer working group report: Jpn J Clin Oncol, 40, i51-i56, 2010. 83. Tanaka N, Miyajima A, Kosaka T, Shirotake S, Hasegawa M, Kikuchi E, Oya M: Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer: Mol Cancer Ther, 9(11), 2982-2992, 2010. 84. Maeda T, Kikuchi E, Matsumoto K, Yazawa S, Hagiuda J, Miyajima A, Nakagawa K, Fujiwara H, Hoshino H, Oya M: Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient: Int J Clin Oncol, 15(5), 508-511, 2010. 85. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Strobel P, Fernandez M, Karakiewcz P, Shariat SF: Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy: Eur Urol, 57(6), 1072-1079, 2010. 86. Yoshimine S, Miyajima A, Nakagawa K, Ide H, Kikuchi E, Oya M: Extraperitoneal Approach Induces Postoperative Inguinal Hernia Compared with Transperitoneal Approach after Laparoscopic Radical Prostatectomy: Jpn J Clin Oncol, 40(4), 349-352, 2010. 87. Shirotake S, Kikuchi E, Matsumoto K, Yazawa S, Kosaka T, Miyajima A, Nakagawa K, Oya M: Role of Pelvic Lymph Node Dissection in Lymph Node-Negative Patients with Invasive Bladder Cancer: Jpn J Clin Oncol, 40(3), 247-251, 2010. 88. Kaneko G, Kikuchi E, Hasegawa M, Miyajima A, Nakagawa K, Kameyama K, Oya M: Non-muscle invasive bladder cancer with concomitantvaginal urothelial carcinoma: a case report and review of the literature: Int J Clin Oncol, 15, 626-630, 2010. 89. Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M, Okada Y, and Oya M: Expression of Snail in upper urinary tract urothelialcarcinoma: Prognostic significance and implications for tumor invasion: Clin Cancer Res, 16(23), 5814-5823, 2010. 90. Yuge K, Miyajima A, Hasegawa M, Miyazaki Y, Maeda T, Takeda T, Takeda A, Miyashita K, Kurihara I, Shibata H, Kikuchi E, Oya M: Initial experience of transumbilical laparoendoscopic single-site surgery of partial adrenalectomy in patient withaldosterone-producing adenoma: BMC Urol, 10, 19, 2010. 91. Sugawara A, Nakashima J, Kunieda E, Nagata H, Asakura H, Oya M, Shigematsu N: Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds: Radiat Oncol, 5,86, 2010. 92. Matsushima M, Kikuchi E, Hasegawa M, Matsumoto K, Miyajima A, Oya M: Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study: BMC Urol, 10, 12, 2010. 93. Matsumoto K, Nakagawa K, Hashiguchi A, Kono H, Kikuchi E, Nagata H, Miyajima A, Oya M: Contrast-enhanced ultrasonography of the prostate with Sonazoid: Jpn J Clin Oncol, 40(11), 1099-104, 2010. 94. Shinoda K, Nakagawa K, Kosaka T, Tanaka N, Maeda T, Kono H, Mizuno R, Kikuchi E, Miyajima A, Umezawa K, Oya M: Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin: Hum Immunol, 71(8), 763-70, 2010. 95. Tanaka N, Kikuchi E, Matsumoto K, Miyajima A, Nakagwa K, Oya M: Frequency of tumor recurrence: A strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer: J Urol, 185(2), 450-455, 2011. 96. Hayakawa N, Kikuchi E, Mikami S, Matsumoto K, Miyajima A, Oya M: The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor: Jpn J Clin Oncol, 42(3), 424-429, 2011. 97. Hagiwara M, Miyajima A, Matsumoto K, Kikuchi E, Nakagawa K, Oya M: Benefit of Laparoscopic Radical Nephrectomy in Patients with a High BMI:Jpn J Clin Oncol, 41(3), 400-4, 2011. 98. Nagamatsu G, Kosaka T, Kawasumi M, Kinoshita T, Takubo K, Akiyama H, Sudo T, Kobayashi T, Oya M, Suda T: A germ cell specific gene, Prmt5 works as somatic cell reprogramming: J Biol Chem, 286(12), 10641-10648, 2011. 99. Maeda T, Kikuchi E, Matsumoto K, Miyajima A, Oya M: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor: J Urol, 185(3), 802-806, 2011. 100. Yuge K, Kikuchi E, Matsumoto K, Takeda T, Miyajima A, Oya M: Could Patient Age Influence Tumor Recurrence Rate in Non-muscle-invasive Bladder Cancer Patients Treated with BCG Immunotherapy? :Jpn J Clin Oncol, 41(4), 565-570, 2011 101. Shirotake S, Miyajima A, Kosaka T, Tanaka N, Maeda T, Kikuchi E, Oya M: Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer: Urology, 77(4), 1009-1010, 2011. 102. Ide H, Kikuchi E, Yasumizu Y, Hattori S, Hasegawa M, Miyajima A, Oya M: Combination treatment of S-1 with CPT-11 to overcome 5-fluorouracil resistance in bladder cancer: Jpn J Clin Oncol, 41, i4-i5, 2011. 103. Kaneko G, Kikuchi E, Matsumoto K, Obata J, Nakamura S, Miyajima A, Oya M: Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer: Jpn J Clin Oncol, 41(7), 908-14, 2011. 104. Matsumoto K, Kikuchi E, Horinaga M, Takeda T, Miyajima A, Nakagawa K, Oya M: Intravesical Interleukin-15 Gene Therapy in an Orthotopic Bladder Cancer Model:Hum Gene Ther, 22(11), 1423-32, 2011. 105. Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M: Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer:J Urol, 185(6), 2376-81, 2011. 106. Suda N, Shibata H, Kurihara I, Ikeda Y, Kobayashi S, Yokota K, Murai-Takeda A, Nakagawa K, Oya M, Murai M, Rainey WE, Saruta T, Itoh H: Coactivation of SF-1-mediated transcription of steroidogenic enzymes by Ubc9 and PIAS1:Endocrinology, 152(6), 2266-77, 2011. 107. Ito Y, Kikuchi E, Tanaka N, Miyajima A, Mikami S, Jinzaki M, Oya M: Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma:J Urol, 185(5), 1621-6, 2011. 108. Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Oya M: Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate: Prostate, 71(14), 1510-7, 2011. 109. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mukai M, Okada Y: Expression of snail and slug in renal cell carcinoma: E-cadherin repressor snail is associated with cancer invasion and prognosis: Lab Invest, 91, 1443-1458, 2011. 110. Kosaka T, Oya M: History and current review of basic research for prostate cancer :Nihon Rinsho,69, Suppl 5, 7-12,2011. 111. Tanaka N, Miyajima A, Kikuchi E, Matsumoto K, Hagiwara M, Ide H, Kosaka T, Masuda T, Nakamura S, Oya M: Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma: British Journal of Cancer, 106, 290-296, 2011. 112. Hasegawa M, Miyajima A, Kosaka T, Yasumizu Y, Tanaka N, Maeda T, Shirotake S, Ide H, Kikuchi E, Oya M: Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer: Int J Cancer, 130(2), 431-42, 2012 113. Sugawara A, Nakashima J, Kunieda E, Nagata H, Mizuno R, Takeda A, Seki S, Shiraishi Y, Kouta R, Oya M, Shigematsu N: Preimplant factors affecting Prostate D90 after transperineal interstitial prostate brachytherapy with loose(125) I seeds : Keio J Med, 61(3), 89-94, 2012. 114. Yazawa S, Kikuchi E, Takeda T, Matsumoto K, Miyajima A, Nakagawa K, Oya M: Surgical and chemotherapeutic options for urachal carcinoma: report of ten cases and literature review: Urol Int, 88(2), 209-14, 2012. 115. Mizuno R, Oya M: Biomarker for molecular targeting therapy against renal cell carcinoma: Gan To Kagaku Ryoho, 39(1), 39-42, 2012. 116. Tanaka N, Miyajima A, Kikuchi E, Matsumoto K, Hagiwara M, Ide H,Kosaka T, Masuda T, Nakamura S, Oya M: Prognonstic impact of renin-angiotensin system blockade in localized upper-tract urothelial carcinoma: Br J Cancer,106(2),290-6,2012. 117. Tsujioka Y, Jinzaki M, Tanimoto A, Nakagawa K, Akita H, Kikuchi E, Okuda S, Mikami S, Oya M, Kuribayashi S.:Radiological findings of primary localized amyloidosis of the ureter: J Magn Reson Imaging, 35(2),431-5, 2012. 118. Oya M: What do we need for eradicating kidney cancer cells?: Int J Urol,19(2),96-7,2012. 119. Hoshino K, Kikuchi E, Tanaka N, Akita H, Ito Y, Miyajima A, Jinzaki M, Oya M : Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.: Jpn J Clin Oncol, 42(3), 202-7, 2012. 120. Shirotake S, Miyajima A, Kosaka T, Tanaka N, Kikuchi E, Mikami S, Okada Y, Oya M: Regulation of monocyte chemoattractant protein-1 through angiotensin ll type 1 receptor in prostate cancer: Am J Pathol, 180(3), 1008-16, 2012. 121. Takeda T, Kikuchi E, Mikami S, Suzuki E, Matsumoto K, Miyajima A, Okada Y, Oya M: Prognostic role of KiSS-1 and possibility of therapeutic modality of metastin,the final peptide of the KiSS-1 gene, in urothelial carcinoma: Mol Cancer Ther,11(4),853-63, 2012. 122. Shirakawa H, Kikuchi E, Mikami S, Fukamachi S, Miyazaki Y, Tanaka N, Miyajima A, Oya M: Three cases of granulocyte colony-stimulating factor-producing urinary upper tract carcinomas: Scand J Urol Nephrol,46(2),136-41,2012. 123. Miyajima A, Hattori S, Maeda T, Hasegawa M, Takeda T, Kikuchi E, Asanuma H, Nakagawa K, Oya M: Transumbilical approach for short-term outcome: Int J Urol,19(4),331-5,2012. 124. Matsumoto K, Kikuchi E, Shirakawa H, Hayakawa N, Tanaka N, Ninomiya A, Miyajima A, Nakamura S, Oya M: Risk of subsequent tumour recurrence and stage progression in bacilli Calmette-Guerin relapsing non-muscle-invasive bladder cancer: BJU Int, 110(11 Pt B), E508-13, 2012. 125. Mizuno R, Asano K, Mikami S, Nagata H, Kaneko G, Oya M: Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma: Jpn J Clin Oncol, 42(5), 442-6, 2012. 126. Nagamatsu G, Kosaka T, Saito S, Takubo K, Akiyama H, Sudo T, Horimoto K, Oya M, Suda T: Tracing the conversion process from primordial germ cells to pluripotent stem cells in mice: Biol Reprod, 86(6), 182, 2012. 127. Kaneko G, Miyajima A, Kikuchi E, Nakagawa K, Oya M: The benefit of laparoscopic partial nephrectomyin high body mass index patients: Jpn J Clin Oncol, 42(7), 619-24, 2012. 128. Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, Maeda T, Ishida M, Miyajima A, Nakagawa K, Okada Y, Sato Y, Oya M: The prognostic significance of vasohibin-1 expression inpatients with upper urinary tract urothelial carcinoma: Clin Cancer Res, 18(15), 4145-53, 2012 129. Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, Miyajima A, Horiguchi Y, Nakashima J, Umezawa K, Shigematsu N, Oya M: Enhancement of radiosensitivity by a unique noel NF-κB inhibitor, DHMEQ, in prostate cancer: Br J Cancer, 107(4), 652-7, 2012. 130. Miyazaki Y, Miyajima A, Maeda T, Ito Y, Tanaka N, Kosaka T, Masuda A, Mizuno R, Kikuchi E, Nakagawa K, Oya M: Renal cell carcinoma arising from a horseshoe kidney in a chronic hemodialysis patient: Clin Exp Nephrol, 16(4), 647-51, 2012. 131. Shirakawa H, Kikuchi E, Tanaka N, Matsumoto K, Miyajima A, Nakamura S, Oya M: Prognostic significance of Bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer: BJU Int,110(6 Pt B), E216-21, 2012. 132. Suzuki K, Mizuno R, Mikami S, Tanaka N, Kanao K, Kikuchi E, Miyajima A, Nakagawa K, Oya M: Prognostic significance of high nuclear grade in patients with pathologic T1a renal cell carcinoma: Jpn J Clin Oncol, 42(9), 831-5, 2012. 133. Fukada J, Shigematsu N, Nakashima J, Ohashi T, Kawaguchi O, Oya M: Predicting pubic arch interference in prostate brachytherapy on transrectal ultrasonography-computed tomography fusion images: J Radiat Res, 53(5), 753-9, 2012. 135. Ito Y, Kikuchi E, Maeda T, Matsushima M, Kono H, Mizuno R, Nagata H, Miyajima A, Nakagawa K, Oya M: Bone scan in patients with newly diagnosed prostate cancer ; To perform or not? : External validation of the currently available guidelines for Japanese patients: The108th American Urological Association Annual Meeting: San Diego: 2013. 5. th 136. Oya M "FHormonal micro-environment of castration resistant prostate cancer: 10 German-Japanese Urological Meeting: Kyoto:2013.6. th 137. Oya M: Resistance to angiogenesis inhibitors in metastatic renal cell carcinoma: The 11 Annual Meeting of Japanese Society of Medical Oncology: Miyagi: 2013.8. 138. Mizuno R, Asanuma H, Kono H, Shinojima T, Kikuchi E, Miyajima A, Nakagawa K, Oya M, Mikami S: Clinical Experience of Xp11:2 Translocation Renal Cell Carcinoma: 33 rd CONGRESS OF THE SOCIETE INTERNATIONALE D’ UROLOGIE : VANCOUVER: 2013.9. th 139. Oya M: Speaker: SymposiumⅢRole of Androgens From Male Development to Male LUTS: The 4 Congress of Asian Pacific Prostate Society: Okinawa: 2014.3. 140. Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M: Dual Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer: The 4th Congress of Asian Pacific Prostate Society: Okinawa: 2014.3. 141. Shinojima T, Mizuno R, Kosaka T, Kikuchi E, Miyajima A, Oya M, D.S.B.Hoon, L.Lessard.: Combinational epigenetic therapy targeting EZH2 and histone deacetylase in prostate cancer cells: Synergic effect on induction of apoptosis and TIMP3 tumor suppressor gene:29 th Annual EAU Congress:Stockholm:2014.4. 142. Oya M :Chairs:Poster Session 53:Renal function and survival after partial nephrectomy: 29th Annual EAU Congress:Stockholm:2014.4. 143. Kaneko G, Miyajima A, Hasegawa R, Mizuno R, Uchida Y, Hara S, Kikuchi E, Nakagawa K, Jinzaki M, Oya M: Visceral obesity is a useful predictor of better recurrence-free survival after curative surgeries for Japanese patients with localized clear cell renal cell carcinoma: 29th Annual EAU Congress: Stockholm: 2014.4. 144. Hak Lee, Ithaar Derweesh, Song Wang, Ramzi Jabaji, Kyle Gilis, La Jolla, Riccardo Autorino, Luis Brandao, S.Jeff Chueh, Jihad Kaouk, Cleveland, Yinghao Sun, Bo Yang, Guo Fei, Shanghai, Deok Hyun, Byong Chang Jeong, Seoul, Francesco Greco, Vincenzo Altieri, Rocca di Neto, Paolo Fornara, Halle Saale, Luca Cindolo, Francesco Berardinelli, Luigi Schips, Vasto, Christian Fiori, Francesco Porpiglia, Orbassano, Xiang Chen, Zhi Chen, Yao He, Changsha, Anibal Branco, Curitiba, Chun-Hou Liao, lason Kyriazis, Evangelos Liatsikos, Patra, Greece, Miyajima A, Oya M: Contemporary minimally invasive management of adrenal disorders: an international multi-institutional Survey: AUA Annual Meeting: Orlando: 2014.5. 145. Hongo H, Shinojima T, Yazawa S, Kanao K, Morita S, Kosaka T, Kono H, Mizuno R, Kikuchi E, Nagata H, Asanuma H, Miyajima A, Nakagawa K, Saito S, Oya M: Development of an algorithm for predicting severe acute epididymitis: AUA Annual Meeting: Orlando: 2014.5. 146. Ito Y, Kikuchi E, Tanaka N, Kosaka T, Mizuno R, Miyajima A, Umezawa K, Oya M: Up-Regulated NFkB Activation is apotent therapapeutic target in acquired platinum-resistant bladder cancer: the efficacy of NFkB blockade by dehydroxymethyl derivative of epoxyquinomicin(DHMEQ): AUA Annual Meeting: Orlando: 2014.5. 147. Yoshimine S, Kikuchi E, Kosaka T, Miyajima A, Oya M: Therapapeutic effect by targeting BCL-XL protein in urothelial carcinoma cells: AUA Annual Meeting: Orlando: 2014.5. 148. Kosaka T, Nagamatsu G, Mikami S, Miyajima A, Yasumizu Y, Miyazaki Y, Kikuchi E, Saito S, Horimoto K, Suda T, Okada Y, Oya M: Drug efficacy reprogramming by ribavirin against the cancer stemness in Docetaxel-Resistant prostate cancer: AUAAnnual Meeting: Orlando: 2014.5. 149. Yasumizu Y, Kosaka T, Miyazaki Y, Kikuchi E, Miyajima A, Oya M: Metabolic shift under hypoxic environment causes resistance to mtor inhibitor in human castration resistant prostate cancer: AUA Annual Meeting: Orlando: 2014.5. 150. Hattori S, Kikuchi E, Kosaka T, Miyajima A, Mikami S, Oya M: AXL is a novel prognostic marker in upper urinary tract urothelial carcinoma: AUA Annual Meeting: Orlando: 2014.5. 151. Ishida M, Mikami S, Kosaka T, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Okada Y, Oya M: Increased expression of aryl hydrocarbon receptor in clear cell renal cell carcinoma and infiltrating lymphocytes: Implications for cancer invasion, prognosis and tumor immunity: AUA Annual Meeting: Orlando: 2014.5. 152. Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y: Prognostic significance of TNF-a and CD44 expression in crear cell renal cell carcinomas: implication of cancer invasion, metastasis, and resistance to sunitinib treatment: AUA Annual Meeting: Orlando: 2014.5. 153. Matsushima M, Kikuchi E, Maeda T, Ando T, Nagata H, Miyajima A, Nakagawa K, Oya M: Erectile function is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy: AUA Annual Meeting: Orlando: 2014.5. 154. Yuge K, Kikuchi E, Hagiwara M, Yasumizu Y, Kosaka T, Miyajima A, Oya M: Nicotine induces tumor aggressiveness and chemoresistance through activation of Pl3K/AKT/MTOR pathway in bladder cancer: AUA Annual Meeting: Orlando: 2014.5. 155. Hagiwara M, Kikuchi E, Kosaka T, Yuge K, Yasumizu Y, Saya H, Oya M: Metformin is a new therapeutic strategy for targeting CD44 variant in bladder cancer: AUA Annual Meeting: Orlando: 2014.5. 156. Yasumizu Y, Kosaka T, Miyazaki Y, Kikuchi E, Miyajima A, Oya M: Post-translational modification mediated by the prolyl isomerase PIN1 accerelate cancer progression incastration resistant prostate cancer: AUA Annual Meeting: Orlando: 2014.5. 157. Fukumoto K, Kikuchi E, Mikami S, Matsushima M, Yuge K, Ogiwara K, Miyajima A, Nakagawa K, Oya M: Impact of lymphovascular invasion status in transurethral resection of bladder tumors could predict subsequent stage progression in T1 bladder tumors: AUA Annual Meeting: Orlando: 2014.5. 158. Kobayashi H, Kikuchi E, Maeda T, Tanaka N, Matsumoto K, Miyajima A, Nakagawa K, Nakamura S, Oya M: Timing of 1st recurrence affects subsequent clinical outcome in 1st recurrent low grade ta bladder cancer: AUA Annual Meeting: Orlando: 2014.5. 159. Ishioka K, Kikuchi E, Maeda T, Hasegawa M, Kosaka T, Shinojima T, Nagata H, Miyajima A, Nakagawa K, Oya M: Prosrective evaluation of efficacy and safety of solifenacin and mirabegron treatment in BPH patients treated with dutasteride but having OAB symptoms: AUA Annual Meeting: Orlando: 2014.5. 160. Matsumoto K, Mizuno R, Tanaka N, Ide H, Hasegawa M, Ishida M, Hayakawa N, Yasumizu Y, Hagiwara M, Hara S, Kikuchi E, Miyajima A, Nakagawa K, Nakajima Y, Nakamura S, Nakashima J, Oya M: Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy: AUA Annual Meeting: Orlando: 2014.5. 161. Yazawa S, Yamamoto H, Shimada M, Kaburaki N, Shinojima T, Koyama M, Takeyama M, Kato K, Sho T, Kiyota H, Iwata S, Oya M, Matsymoto T: Nationwide survey on periorerative management and surgical site infection of patients who underwent transvaginal mesh for treatment of pelvic organ prolapse: AUA Annual Meeting: Orlando: 2014.5. 162. Obata J, Kikuchi E, Tanaka N, Shirotake S, Matsumoto K, Oyama M, Kanao K, Kobayashi H, Miyazaki Y, Ide H, Ishioka K, Miyajima A, Momma T, Nakagawa K, Oya M: The predictive value of C-REACTIVE protein for prognosis in patients with metastatic upper tract urothelial carcinoma treated with CISPLATIN-BASED chemotherapy following radical nephroureterectomy: MULTI-INSTITUTIONAL study: AUA Annual Meeting: Orlando: 2014.5. 163. Mizuno R , Kosaka T, Mikami S, Oya M Efficacy of axitinib in patients with metastatic renal cell carcinoma previously treated with both VEGFR-TKI and mTORI.: 2014 ASCO Annual Meeting: Chicago:2014.5. 164. Kosaka T, Miyazaki Y, Miyajima A, Mizuno R, Mikami S, Daimon T, Kikuchi E, Nakagawa K, Sato Y, Oya M The prognostic significance of vasohibin-1 expression in patients with prostate cancer.: 2014 ASCO Annual Meeting: Chicago:2014.5. 165. Daimon T, Kosaka T, Mikami S, Miyazaki Y, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Sabe H, Oya M Erythrocyte protein band 4.1-like5 expression in patients with upper urinary tract urothelial carcinoma correlates with tumor recurrence.: 2014 ASCO Annual Meeting: Chicago:2014.5. 166. Miura Y, Chiyo K, Imamura, Uchino K, Kishida T, Matsubara N, Shinojima T, Oya M, Nakaigawa N, Yoshimura K, Takano T, Tanigawara Y; Dose adjustment of axitinib based on AUC monitoring in sunitinib-refractory advanced renal cell carcinoma.: 2014 ASCO Annual Meeting: Chicago:2014.5. 167. M Oya:Chairs: Poster Session 34: Imaging in the management of renal tumours: 30th Annual EAU Congress: Madrid: 2015.3. 168. Matsumoto K, Hayakawa N, Morita S, Shinoda K, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Miyajima A, Oya M: Bladder metastasis from renal cell carcinoma: Retrospective analysis of 65 reported cases: 30th Annual EAU Congress: Madrid: 2015.3. 169. Fukumoto K, Miyajima A, Hattori S, Morita S, Shinoda K, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Jinzaki M, Oya M: What changed after mastering surgical skills in laparoendoscopic single-site adrenalectomy?: 30th Annual EAU Congress: Madrid: 2015.3.